Trial Profile
Phase I Trial of Copper Chelator in Conjunction With Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-resistant/-Refractory Epithelial Ovarian Cancer, Tubal Cancer and Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Trientine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms Trientine
- 18 Oct 2020 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 New trial record